分子状水素の臨床的有効性：不活性ガスから医療応用へ
Molecular hydrogen (H2) first emerged as an experimental biomedical agent roughly four decades ago, and accumulating clinical trial data over the past several years have begun to substantiate its medical utility. Evidence from multiple trials indicates improvements in clinical endpoints and surrogate markers across a range of conditions, including metabolic disorders, chronic systemic inflammatory diseases, and cancer. This review consolidates available clinical data on H2, addressing pharmacological considerations such as dosing, routes of administration, potential adverse reactions, and applicability in specific patient populations. The resulting clinical profile is intended to provide an evidence-based framework to guide both practical use and future research directions for the broader healthcare research community.
H2 is proposed to exert selective scavenging of reactive oxygen species and modulate oxidative stress- and inflammation-related pathways, contributing to improvements across diverse clinical endpoints.
This study combines multiple delivery routes. As a general principle, the most efficient route for routine hydrogen intake is inhalation. Inhalation carries explosion risk (empirical LFL of 10%; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/25936365